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OBJECTIVES: This study aimed to analyze clinical and laboratory parameters and their association with long-
term outcomes in patients who underwent liver transplantation for hepatocellular carcinoma treatment,
according to the etiology of the underlying chronic liver disease, in order to identify predictors of response to
this therapeutic modality.
METHODS: Demographic, clinical, and laboratory data from a cohort of 134 patients who underwent orthotopic
liver transplantation for hepatocellular carcinoma treatment at a referral center in Brazil were retrospectively
selected and compared according to the etiologic group of the underlying chronic liver disease. Events, defined
as tumor recurrence or death from any cause, and event-free survival were also analyzed, and multivariate
analysis was performed.
RESULTS: The etiologies comprised hepatitis C and B virus infection, alcohol abuse, and cryptogenic disorder.
Although liver transplantation was performed outside the Milan criteria in 33.3% of the subjects, according to
pathologic examination of the explanted liver, the Model for End-Stage Liver Disease score was low (o22) in
most patients (70.6%) and recurrence was identified in only 10 (7.9%) patients. Events occurred in 37 patients
(28.5%), and the median event-free survival was 75 months (range, 24-116 months). No difference among
etiologic groups was found in the parameters analyzed, which were not independently associated with
outcome.
CONCLUSION: Clinical and laboratory characteristics according to etiologic groups were not different, which
might have led to comparable long-term outcomes among these patient groups and failure to identify predictors
that could aid in better selection of subjects for liver transplantation in the management of this cancer.
KEYWORDS: Hepatocellular Carcinoma; Liver Transplantation; Liver Cirrhosis; Recurrence.
’ INTRODUCTION
Hepatocellular carcinoma (HCC), the fourth leading cause
of cancer mortality worldwide, is a complex and poorly under-
stood disease (1,2). It arises in the context of progressive
underlying chronic liver disease (CLD) due to etiologies that
are very common worldwide, such as hepatitis B (HBV) and C
(HCV) virus infection, excessive alcohol consumption, auto-
immune hepatitis, nonalcoholic fatty liver disease (NAFLD),
inherited metabolic disorders, and other nonidentified etiolo-
gies, called cryptogenic etiologies (3).
Only 30-40% of all HCCs are diagnosed at an early stage,
for which there are potential curative treatment options, such
as liver transplantation (LT) (4). In Europe and the United
States, nearly 25-35% of all LTs are performed to treat HCCs
(5). In Brazil, where the HCC incidence among patients under
surveillance programs is about 2.8% each year (6), there is a
report stating a similar proportion – around 33% of LTs (7).
After a period of unrestricted LT indications for treating
HCC, the Milan criteria (MC) were introduced in 1996, andDOI: 10.6061/clinics/2020/e1529
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are currently a well-established predictor of HCC recurrence
(8). These criteria rely on imaging findings, and set restrictive
limits based on the size and number of tumors to select
candidates for LT. Patients whose tumor burden is within the
MC have a 4-year recurrence rate after transplantation of less
than 10%, whereas it is about 41% for those with a tumor
burden outside the MC (8).
However, the MC have some limitations because the
tumor biology, another important determinant of the risk of
tumor recurrence after LT, is not taken into account (9). Thus,
it is necessary to identify other prognostic and predictive
parameters of HCC recurrence. Some studies suggest that
pre-LT serum levels of alpha-fetoprotein (AFP), a biomarker
used for HCC surveillance and diagnosis, have prognostic
utility in monitoring HCC patients treated with LT; however,
the cutoff values have not yet been established (9). Moreover,
attempts have been made to determine other pathological
features and relevant clinic data associated with HCC recur-
rence, but the results have not yet been validated (10,11).
As HCC is a heterogeneous disorder, with multiple etio-
logic factors (12), it is possible that there may be differences
among the characteristics of the HCC patients as well as
long-term outcomes. Therefore, this study aimed to investi-
gate pre-LT clinical and laboratory parameters in patients
with HCC related to different etiologies of CLD in a Brazilian
population, correlate these findings with the risk of HCC
recurrence, and investigate if there is any clinical or labo-
ratory marker that may improve the performance of the MC
in predicting HCC recurrence after LT.
’ METHODS
Cohort
Patients with HCC who underwent LT at Hospital das
Clínicas, Universidade Federal de Minas Gerais, a Brazilian
referral center, between 1998 and 2015, were identified
(n=156). The protocol of this institution follows the Interna-
tional Working Party recommendations for HCC diagnosis
(13). All patients had archived formalin-fixed, paraffin-
embedded tissue of the explanted liver. No histological
review was specifically performed for this study, and
patients without a definitive diagnosis of HCC (n=3) by
histological examination or immunohistochemical analysis
were not included in the database.
Demographic and clinical pre-LT data of each patient were
retrospectively collected from the medical records. We
searched for data regarding sex; age; etiology of the
underlying CLD; MELD (Model For End-Stage Liver
Disease) and CHILD-Pugh scores – prognostic models that
estimate the severity of the underlying liver condition
(14,15); number of nodules; size of the greatest nodules;
MC determined by pathologic examination of the explanted
liver (pathologic MC); diabetes mellitus; AFP levels; hemo-
globin levels; international normalized ratio (INR); serum
albumin levels; bilirubin levels; liver enzyme levels (aspar-
tate aminotransferase [AST], alanine aminotransferase [ALT],
gamma-glutamyltransferase [GGT], alkaline phosphatase
[AF]); and lactate dehydrogenase (LDH) levels. As there were
only a few cases (n=6) of CLD caused by autoimmune and
metabolic disorders, they were not included in the study.
In this study, an event was defined as tumor recurrence or
death from any cause. If the patient presented with multiple
occurrences, only the first event was counted. Event-free
survival (EFS) was defined as the time interval between the
LT date and the occurrence of the event or the end of the
follow-up period. This information was also obtained from
the medical records, but in eight cases, we needed to contact
the patient or family by telephone because the patient’s
follow-up after LT had been conducted at another institution.
The end date of the follow-ups was December 20, 2017.
In situations in which data could not be accessed, such as
missing information in medical records or loss to follow-up,
analyses were performed considering only the available infor-
mation. Patients with very incomplete data in the medical
records of our institution (i.e. clinical and laboratorial data
and surveillance, simultaneously), whose information could
not be recovered from another source (n=13), were excluded
(Figure 1).
Before beginning the study, this study was approved by
the Ethics Committee of the Universidade Federal de Minas
Gerais (CAAE – 44573615.7.0000.5149), and the protocols
were in accordance with the ethical guidelines of the 1975
Helsinki Declaration. Written informed consent was obtained
from the patients or their relatives. The LTs were orthotopic
and exclusively from deceased donors, and the candidates
were enrolled in a central waiting list.
Statistical analysis
Descriptive statistics were used to summarize the data.
A normality test (Shapiro-Wilk) was performed for each con-
tinuous variable. Categorical data are presented as numbers
and percentages, and continuous data are expressed as
medians and interquartile ranges. Categorical variables were
compared between groups of the four most common etio-
logies of underlying CLD (alcoholic, B or C viral hepatitis, or
cryptogenic) using the chi-square test or Fisher’s exact test,
as appropriate. For the comparison of continuous data, we
used the Mann-Whitney U test or the Kruskal-Wallis test, as
appropriate. In multiple comparisons, Bonferroni correction
was applied, when necessary.
Kaplan-Meier curves were constructed to estimate the
probability of surviving, considering the four etiological
groups and the two main categories (viral and non-viral).
The log-rank test was used to compare the curves. A Cox
regression model was performed to determine the character-
istics that were independently associated with EFS. Further-
more, we assessed the associations between these clinical and
laboratory parameters and HCC recurrence or death unrela-
ted to the cancer recurrence, separately, i.e., as two independent
outcomes. For this analysis, we used the multivariate Poisson
regression model with covariance structure. Clinical and labo-
ratory variables that were associated with the outcome in the
univariate analysis (po0.20) were included in the multivariate
model. Statistical significance was assumed at po0.05. Statis-
tical analysis was carried out using SPSS software, version 20
(SPSS, Chicago, IL).
’ RESULTS
Patients’ demographic and laboratory characteristics accord-
ing to the CLD etiology are summarized in Table 1. Among
the 134 patients analyzed, HCCwas related to HCV infection in
59 (61.5%), alcohol abuse in 37 (27.6%), cryptogenic disorder in
18 (13.4%), and HBV infection in 10 (7.5%).
Even though the MC were used to select LT candidates to
treat HCC, in 41 of 123 (33.3%) patients, the procedure was
performed outside these criteria, considering the pathological
examination results of the liver explant. A total of 26/126 (20.6%)
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patients underwent LT despite having four or more nodules. The
median size of the biggest liver nodule was 2.7 cm (range, 2-4
cm). The majority (70.6%) of patients underwent LT with a
MELD score below 22, and the cirrhosis was scored CHILD-
Pugh C in only 15 of 113 individuals (13.3%). The median AFP
serum levels were 12 ng/mL (range, 4.9-58.6 ng/mL). No
significant difference concerning AFP levels was found among
the four etiologic groups in which the patients were categorized.
Comparing the demographic and laboratory parameters
between these groups, the variables were well balanced,
apart from sex (p=0.02) and hemoglobin (p=0.004), AST
(p=0.001), and ALT (po0.001) levels, as shown in Table 1.
HCCs due to alcoholic liver disease were more common in
men (97.3% of all cases assigned to this etiology), whereas in
women, the main etiology was HCV infection (30.4%).
Hemoglobin levels were lower in the alcoholic liver disease
group (12.1 g/dL) than in the HCV (13.5 g/dL, p=0.001) and
HBV groups (14.7 g/dL, p=0.018), but severe anemia was not
found. Both AST and ALT serum concentrations were lower
in the alcoholic liver disease group (52 U/L and 32.5 U/L,
respectively) than in the HCV group (91.5 U/L, po0.001 and
75 U/L, po0.001). In addition, ALT levels were lower (39.5
U/L) in the cryptogenic group than in the HCV group
(75 U/L, po0.01).
In the HBV group, none of patients analyzed had diabetes,
but, despite that, there was no significant difference between
the etiologic groups (p=0.192) concerning the presence of this
condition. Considering all the etiologic groups, diabetes was
present in 37 (31.9%) of the patients.
Globally, as shown in Table 2, disease recurrence was
identified in 10 (7.9%) of 127 patients, although it may also
have occurred in patients who died without observation of
recurrence. Clinically evident recurrence, followed by death,
was observed in six patients. The event rate was 28.5% (37
recurrences or deaths from any cause in 130 patients analyzed).
Events seemed to be more frequent in the HCV group,
in which 20 (54%) recurrences or deaths were observed.
Nevertheless, there was no significant difference between the
etiologic groups (p=0.690). The median follow-up period was
53 months (range 1-97 months), and four patients were lost
to follow-up.
On survival analysis, the median EFS was 75 months
(range, 24-116 months). The overall rate of EFS at 12 and
24 months was 83.1% and 82.2%, respectively. Analyzing the
four etiologic groups, the Kaplan-Meier curve (Figure 2)
showed overlap of the curves (p=0.665). The same was seen
when the patients were classified in viral and non-viral etio-
logic groups, as showed in Figure 3.
No demographic or laboratory variables, including the
pathologic MC, were found to be related to the risk of event,
as demonstrated in both univariate and multivariate
analyses (Table 3). Even when HCC recurrence and death
unrelated to the cancer recurrence were considered sepa-
rately as outcomes, no independent association could be
demonstrated.
’ DISCUSSION
In this study, we found no significant differences in HCC
recurrence or mortality profiles among patients who under-
went LT to treat HCC in the comparison of the four major
etiologic groups underlying CLD. Moreover, similarities in
demographic, clinic, and laboratory pre-LT parameters were
observed among these four etiologic groups. These simila-
rities, especially the comparable severity of the underlying
liver condition among the groups, could be responsible,
at least partially, for failing to identify any predictor of
recurrence.
Despite refined selection criteria and advances in pre-
operative staging, recurrence of HCC after LT is still an
Figure 1 - Study diagram flow. HCC: hepatocellular carcinoma; HBV: hepatitis B virus; HCV: hepatitis C virus; DM: diabetes mellitus.
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unsolved issue. There are several studies showing different
rates of recurrence (range, 6.4-18.3%) (16-23]. One explanation
for this difference could be the time spent on a transplant
waiting list. In regions in which this time is short, LT may be
performed in candidates with an aggressive tumor biology,
among whom high recurrence rates are expected (11). In
contrast, in regions in which the waiting time is longer, tumors
with an aggressive biology could progress beyond the MC and
thus LT is not performed (11). Our findings showed at least
7.5% disease recurrence, which is comparable to the findings of
the United Network for Organ Sharing database (23). It is
important to highlight that the median follow-up period in our
study was only about 53 months.
As recurrence may also have occurred in patients who
died without being counted, we defined tumor recurrence
or death as events. We found no difference regarding EFS
among the etiologic groups. However, when EFS at 12 and
24 months was compared, we observed that most events
occurred within the first year of LT, and thereafter, there
was a tendency for EFS to plateau. Therefore, it is possible
to conclude that many deaths could not be ascribed to
HCC recurrence but to non-cancer-related causes, such as LT
complications, which are expected to occur within the first
few months after the procedure.
Despite the existence of expanded criteria, of which most
are not externally validated, the MC are still a useful tool to
Table 1 - Demographic and laboratorial characteristics according to CLD etiology.
Overall HCV HBV Alcohol Cryptogenic p-value
N (%) 134 (100.0) 59 (61.5) 10 (7.5) 37 (27.6) 18 (13.4)
Age (years)h 57.7 57.0 56.5 57.0 62.5 0.066
(52.0-63.0) (51.5-61.5) (40.5-63.5) (51.5-63.5) (47.5-66.2)
Sexd F 27 (20.1) 21 (35.5)* 1.0 (10.0) 1 (2.7) 4.0 (22.2) 0.020
M 107 (79.9) 38 (64.5) 9 (90.0) 36 (97.3)* 14.0 (77.8)
MELDd p22 84/119 (70.6) 42 (71.2) 5/9 (55.6) 24/33(72.7) 13 (76.4) 0.682
23-29 33/119 (27.7) 16 (27.1) 4/9 (44.4) 9/33 (27.3) 4 (23.5)
429 2/119 (1.7) 1 (1.7) 0/9 (0) 0/33 (0) 1 (5.6)
CHILDd A 49/113 (43.4) 27/53 (50.9) 6/9 (66.7) 11/34 (32.4) 5/17 (29.4) 0.202
B 49/113 (43.4) 22/53 (41.5) 2/9 (22.2) 17/34 (50.0) 8/17 (47.1)
C 15/113 (13.3) 4/53 (7.5) 1/9 (11.1) 6/34 (17.6) 4/17 (23.5)
AFP (ng/mL)h 12.1 17.0 19.4 6.1 8.5 0.421
(4.9-58.6) (6.7-72.4) (3.2-694.0) (4.1-43.7) (4.6-79.6)
Number of nodulesd 1 63/126 (50.0) 25/58 (43.1) 6 (60.0) 21 (56.8) 8 (44.4) 0.571
2 28/126 (22.2) 15/58 (25.9) 2 (20.0) 5 (13.5) 6 (33.3)
3 9/126 (7.1) 6/58 (10.3) 0 (0.0) 3 (8.1) 0 (0.0)
43 26/126 (20.6) 13/58 (20.7) 2 (20.0) 8 (21.6) 4 (22.4)
Size biggest nodule (cm)h 2.7 3.0 2.8 2.5 3.2 0.411
(2.0-4.0) (2.05-3.85) (1.75-4.25) (1.5-3.3) (1.0-5.0)
MCd Yes 82/123 (66.7) 38/58 (65.6) 7 (70.0) 26 (70.3) 11 (61.1) 0.890
No 41/123 (33.3) 20/58 (34.4) 3 (30.0) 11 (29.7) 7 (38.9)
Hb (g/dL)h 13.0 13.5 14.7 12.1* 12.4 0.004
(11.9-14.4) (12.7-14.6) (12.8-15.7) (11.3-13.2) (10.7-14.4)
AST (U/L)h 71.0 91.5 50.0 52.0* 54.5 0.001
(45.0-104.0) (58.5-138.2) (41.0-80.5) (33.5-78.8) (41.8-91.8)
ALT (U/L)h 55.0 75.0 51.0 32.5* 39.5* o0.001
(32.7-82.7) (54.0-102.5) (42.0-70.5) (24.0-55.0) (29.8-61.3)
Alkaline phosphatase (U/L)h 152.5 140.0 174.0 153.0 206.5 0.247
(104.0- 234.0) (101.5-213.5) (77.0-283.0) (106.2-253.7) (129.2-283.5)
LDH (U/L)h 436.0 441.5 410.0 426.0 495.0 0.803
(324.0-586.0) (327.7-618.2) (316.0-736.0) (300.0-566.0) (35.05-660.0)
Diabetesd Não 79/116 (68.1) 39 (66.1) 7/7 (100.0) 20/33 (60.6) 13/17 (76.5) 0.192
Sim 37/116 (31.9) 20 (33.9) 0/7 (0.0) 13/33 (39.4) 4/17 (23.5)
Data are expressed as absolute numbers (percentage) or median (interquartile range). Number of patients with the characteristic/number for whom the
information was available.
CLD: chronic liver disease; HBV: hepatitis B virus; HCV: hepatitis C virus; F: Female; M: Male; MELD: Model for End-Stage Liver Disease; CHILD: CHILD-Pugh
score; MC: Milan criteria; Hb: Hemoglobin; AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate
dehydrogenase.
* Refers to statistically significant difference. d Exact Fischer test h Kruskal-Wallis test.
Table 2 - Clinical outcomes according to chronic liver disease etiology.
All etiologies HCV HBV Alcoholic Cryptogenic p-value
Recurrence 10/127 (7.9%) 8/63 (12.7%) 1/10 (10.0%) 1/36 (2.8%) 0/18 (0.0%) 0.173
Event 37/130 (28.5%) 20/65 (30.8%) 4/10 (40.0%) 9/37 (24.3%) 4/18 (22.2%) 0.690
EFS 75 (24.0-116.0) 87.5 (35.5-122.8) 60.5 (6.0-99.0) 69 (26.2-96.2) 76 (1.5-113.5) 0.228
Data are expressed as absolute numbers (percentage) and median (interquartile range).
Number of patients with analyzed outcome/number for whom the information was available.
HBV: hepatitis B virus; HCV: hepatitis C virus; EFS: event-free survival (months).
Fisher’s exact test was used.
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select HCC patients for LT, and recurrence is more frequent
for transplantations outside these criteria (8). In our institu-
tion, LT is performed only for patients fulfilling the MC
(preoperative imaging with a single lesion o5 cm or up to
three lesionsp3 cm), but our study showed that 33.3% of the
patient who underwent LT for HCC treatment were, indeed,
outside this criteria based on pathological analysis of explant
liver. One possible explanation for this finding is a long time
Figure 2 - Kaplan-Meier curves of event-free survival in HCC patients according to the etiologic groups of chronic liver disease.
Figure 3 - Kaplan-Meier curves of event-free survival in HCC-patients of viral and non-viral etiologic groups of underlying chronic liver
disease.
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on the waiting list for cadaveric organ donation, during
which oligoprogression of the disease could occur. In order
to minimize misclassification of tumor extension before LT,
the Brazilian government’s rules state that it is necessary
to update imaging exams every three months; however,
it is known that oligoprogression could occur in tumors
with more aggressive behavior, even in this short period.
However, the pathological MC were not associated with any
differences in EFS in our investigation.
It is worth highlighting that MC are based on imaging
methods, and in the present study, the lesions were counted
and measured through pathologic examination of the
explanted liver. Thus, our patients were classified according
to MC, considering the pathological information, by a group
of experienced liver pathologists at our institution. It is
known that the sensitivity for identifying HCC preopera-
tively by computed tomography and magnetic resonance
imaging has limitations, especially for lesions smaller than
1 cm in diameter (24,25). Therefore, some lesions may have
been missed by these imaging methods because of technique-
related limitations, measuring errors, or variations in the
diameter. These possibilities must have influenced our results.
In this setting, a pre-LT imaging review and subsequent
analysis would be relevant, but it was not feasible because
many of the scans were not performed in our institution,
which we consider a limitation of our study.
The MC are considered a good predictor of tumor response
to therapy, but they have limitations, and attempts have been
made to identify clinical variables that may distinguish
patients at higher risk of disease recurrence after LT (9-11).
Some studies showed a higher recurrence risk in patients with
AFP 4200 ng/mL, even within the MC (9,26). In addition to
this well-recognized predictor, we analyzed other demo-
graphic and laboratory parameters such as age, hemoglobin
levels, INR, liver enzymes, and presence of diabetes, and
found no predictor of HCC recurrence. Women were more
likely to have an HCV etiology, and excessive alcohol intake
was the most common etiology in men. Hemoglobin levels
were slightly lower in the alcoholic liver disease group and
some small differences between groups were observed
regarding aminotransferases concentrations, but these factors
did not translate into clinical significance.
HCC is a heterogeneous disease and multiple etiologic
factors involved can lead to cancer development by different
mechanisms (27). Thus, there may be differences in biologic
behavior which can translate into clinical outcomes. Retro-
spective analysis of sorafenib phase III studies in advanced
HCC demonstrated that HCV-positive patients had greater
benefits from the treatment than did patients with other
etiologies (28,29). The phase II study EVOLVE-1 did not
demonstrate any benefit of the mTOR inhibitor everolimus
on the treatment of advanced HCC, and tumor heterogeneity
was suggested as a possible explanation for the poor per-
formance of targeted therapies (30). However, concerning the
etiology of the underlying CLD, our study showed no dif-
ference in EFS. Furthermore, despite 54% of all events having
occurred in the HCV group, the comparison of the event
frequency among the groups was not statistically significant,
even when grouped as viral and non-viral etiologies.
One important aspect is that our study was conducted
in patients who were candidates for LT, which means that
the disease was not as advanced as in the above-mentioned
studies. Therefore, it is possible that different biological
behavior could not translate into clinical outcomes in early
disease stages. In 2007, a study conducted in patients with a
similar profile showed that cryptogenic cirrhosis was more
common in those with recurrent HCC, but this finding was
limited because of the small sample size (10).
An important and well-recognized aspect of HCC needs to
be mentioned. Liver cirrhosis causes a significant impact on
functional liver reserve and is a determinant of the morbidity
and mortality associated with HCC (31). Thus, we assessed
the severity of the underlying CLD by the CHILD-Pugh
score (15), and more than 80% of our patients had scores A or
B, indicating that the cirrhosis was not so severe. No
significant differences between the etiologic groups were
seen. This can explain the relatively long EFS. Moreover, the
MELD score (14), a score used to allocate patients in the
waiting list for a cadaveric organ according to the severity of
cirrhosis, was also analyzed. A large majority of the patients
had scores p22 and no differences between the groups were
noted. In the HBV group, only five (55.6%) of nine patients
had scores below this level, suggesting more severe liver
dysfunction in this group; however, it included a limited
number of patients and the comparison with the other etio-
logic groups did not reach statistical significance. In Brazil,
candidates for LT for HCC treatment receive a special MELD
score (7); thus, this is not a good scenario to assess the
severity of the underlying CLD.
Despite being a single-center, retrospective study that may
harbor selection and information bias, this is an important
cohort in which long-term outcomes of LT for the treatment
of HCC in a poor-income country were evaluated. As geo-
graphic variation in biologic and molecular behaviors of
HCC, as well as in the etiology of the underlying CLD, may
exist, studies like this are important in elucidating the com-
plexity of the disease. Considering patients who underwent
LT, future studies correlating clinical and laboratory para-
meters with molecular features are possible because the
patients’ tumor specimens are available, unlike the case in
Table 3 - Association between clinical and laboratorial parameters and EFS survival.
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Hb 0.97 (0.93-1.01) 0.241 -- --
LDH 1.00 (0.99-1.01) 0.090 1.00 (0.99-1.01) 0.168
AST 1.00 (0.99-1.03) 0.124 1.00 (1.00-1.03) 0.180
MELD 0.94 (0.77-1.15) 0.593 -- --
MC 1.17 (0.95-1.44) 0.124 1.23 (0.97-1.55) 0.070
Etiology 0.91 (0.76-1.08) 0.278 -- --
HR: hazard ratio; CI: confidence interval; Hb: hemoglobin; LDH: lactate dehydrogenase; AST: aspartate aminotransferase; MELD: Model for End-Stage
Liver Disease; MC: Milan criteria; EFS: event-free survival.
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many HCC patients whose diagnosis is based on non-
histological criteria.
This study did not aim to perform a complete histological
review of the explanted livers. However, available evidence
suggests that histopathological features, such as grade of
differentiation and histological type, are relevant in predict-
ing HCC growth rate and its biological behavior (32). In this
context, less differentiated tumors and the non-trabecular
type (acinar and solid patterns) have been demonstrated to
be associated with a higher tumor growth rate and a higher
risk of metastasis (33,34). Likewise, the presence of micro-
vascular invasion has been considered a reliable predictor of
tumor recurrence (34). Moreover, the relationship between
tumor and underlying CLD may also provide important
information concerning prognosis; for instance, the presence
of a peritumoral capsule is associated with a better outcome
after hepatic resection (35,36). Thus, histopathological analysis
could identify relevant associations with HCC outcome and
should be investigated in further studies.
Another limitation of our investigation is the reduced
number of patients in the HBV group. Since the implementa-
tion of HBV vaccination by the Brazilian public health system,
as well as improved access to antiretroviral treatment, HBV
infections have decreased in our country (37). Finally, HCC
due to NAFLD was not considered as a separate group but
is probably included in the cryptogenic etiology, despite
diabetes prevalence not being higher in this group. This
condition was only recently recognized as an etiology of
HCC, and the exact prevalence of HCC in cirrhotic NAFLD
remains unknown (38).
Although the multiple etiologies of CLD and HCC hetero-
geneity may be determinant factors of response to LT for
HCC treatment, our results did not demonstrate any dif-
ference regarding the etiology of the CLD and EFS in HCC
patients treated with LT. More studies are needed to identify
biomarkers with a predictive value to overcome the limi-
tations of MC in predicting outcome and to contribute to
appropriate selection of HCC patients for this modality of
treatment.
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